Ask the Experts: Clinical Case Studies
Focusing on Non-statin Therapies for Treating Patients with Hypercholesterolemia

Presented as a Live Webinar

Wednesday, March 1, 2017
1:00 p.m. – 2:00 p.m. ET

On-demand Activity

Live webinar recorded and archived to be watched at your convenience
Available after May 15, 2017

www.ashpadvantage.com/go/pcsk9inhibitors

Planned by ASHP Advantage and supported by educational funding provided by Amgen and an independent educational grant by Sanofi US and Regeneron Pharmaceuticals.
Ask the Experts: Clinical Case Studies Focusing on Non-statin Therapies for Treating Patients with Hypercholesterolemia

Activity Overview

This activity will focus on current issues related to the use of non-statin therapies for treating patients with hypercholesterolemia. The faculty will address the key issues and provide practice pearls for pharmacists.

The content for this activity is based on questions and comments from participants at a recent educational symposium on this topic. Time for additional questions from the webinar audience will be provided at the end of the presentation.

Learning Objectives

At the conclusion of this Application-based educational activity, participants should be able to

- Describe the evidence evaluating reduction in cardiovascular events with statin and non-statin combination therapy.
- Evaluate the use of non-statin therapies for the treatment of hypercholesterolemia in patients who cannot achieve desired LDL-C.
- Evaluate the use of non-statin therapies for the treatment of hypercholesterolemia in patients who report statin related muscle symptoms.

Continuing Education Accreditation

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity provides 1.0 hours (0.10 CEUs – no partial credit) of continuing pharmacy education credit.

Live Activity ACPE #: 0204-0000-17-402-L01-P
On-Demand Activity ACPE #: 0204-0000-17-402-H01-P
Faculty

Joseph Saseen, Pharm.D., BCPS, BCACP
Professor & Vice Chair
University of Colorado Anschutz Medical Campus
Aurora, Colorado

Joseph Saseen, Pharm.D., is Professor of Clinical Pharmacy and Family Medicine, and Vice-Chair of the Department of Clinical Pharmacy at the University of Colorado. He is Clinical Pharmacy Specialist in family medicine, Director of the PGY2 Ambulatory Care residency program and is a Board Certified Pharmacotherapy Specialist (BCPS) and Board Certified Ambulatory Care Pharmacist (BCACP).

Dr. Saseen received his Bachelor of Science degree in pharmacy and his Doctor of Pharmacy degree from the University at Buffalo. He completed a fellowship in ambulatory care research at the University of Colorado Health Sciences Center.

At the University of Colorado, Dr. Saseen participates in research related to the pharmacotherapy of chronic diseases (e.g., hypertension, dyslipidemia) and program grants related to the expansion of ambulatory care clinical services.

Dr. Saseen is a Fellow of the American Society of Health-System Pharmacists, American College of Clinical Pharmacy, and National Lipid Association. He is a past member and Chair of the Board of Pharmacy Specialties and is a board member of the National Lipid Association. He has several publications related to the pharmacotherapy of cardiovascular and was recipient of the American College of Clinical Pharmacy 2014 Education Award and the American Associations of Colleges of Pharmacy 2016 Teaching Innovations.
Ask the Experts: Clinical Case Studies Focusing on Non-statin Therapies for Treating Patients with Hypercholesterolemia

Kim K. Birtcher, Pharm.D, M.S., BCPS-AQ Cardiology, CLS, CDE, AACC, FNLA
Professor
University of Houston College of Pharmacy
Clinical Pharmacist
Kelsey-Seybold Clinic
Houston, Texas

Kim K. Birtcher, Pharm.D., is Clinical Professor at the University of Houston College of Pharmacy and clinical pharmacist at the Kelsey-Seybold Cardiology Clinic in Houston.

Dr. Birtcher received her Bachelor of Science degree in pharmacy and Master of Science degree in pharmacy administration from the University of Texas at Austin. She received her Doctor of Pharmacy degree from the University of Florida.

As a clinical pharmacist at the Kelsey-Seybold Cardiology Clinic in Houston, Texas, she is responsible for treating patients at the Secondary Prevention Lipid Clinic. Her teaching and research interests are in cardiovascular risk reduction and quality improvement initiatives.

Dr. Birtcher is a board certified pharmacotherapy specialist with additional qualifications in cardiology, a certified diabetes educator, and a clinical lipid specialist. She is an Associate of the American College of Cardiology (AACC) and a fellow of the National Lipid Association (FNLA). Dr. Birtcher is active in the American College of Cardiology (ACC), serving as the Co-Chair for the Cardiovascular Team Section’s Working Group for Clinical Pharmacists. She is a member of the ACC/AHA Task Force on Clinical Practice Guidelines and the past Co-Chair of the LDL: Address the Risk Initiative launched by the ACC.
Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

- Faculty and planners report no financial relationships relevant to this activity.
Learning Objectives

- Describe the evidence evaluating reduction in cardiovascular events with statin and non-statin combination therapy.
- Evaluate the use of non-statin therapies for the treatment of hypercholesterolemia in patients who cannot achieve desired LDL-C.
- Evaluate the use of non-statin therapies for the treatment of hypercholesterolemia in patients who report statin related muscle symptoms.

Case 1

- 40-year-old man being evaluated for lipid management
- PMH: heterozygous familial hypercholesterolemia (HeFH), MI 2 years ago, hypertension
- Meds: rosuvastatin 40 mg po daily, carvedilol 12.5 mg po twice daily, ramipril 10 mg po daily, aspirin 81 mg po daily
- States adherence to medications + lifestyle modifications (heart healthy diet, exercises four times weekly)
- LDL-C: Baseline 360 mg/dL, currently 170 mg/dL (∆ >50%)
- Was a 1-pack per day cigarette smoker prior to his MI, but no longer smokes

ACC/AHA 2013 Blood Cholesterol Guideline: Four ASCVD Statin Benefit Groups

- High-intensity statin if age ≤75 yr
- Moderate-intensity statin if age >75 yr or not candidate for high-intensity

ACC/AHA 2013 Blood Cholesterol Guideline: LDL-C ≥190 mg/dL

Class I Recommendations

- If ≥21 years of age should be treated with statin therapy:
  - High-intensity statin therapy unless contraindicated

Class IIa Recommendations

- Reasonable to achieve at least a 50% LDL-C reduction.

Class IIb Recommendation

- After the maximum intensity of statin therapy achieved, addition of a non-statin drug may be considered
Which of the following changes to this patient’s regimen will reduce his LDL-C value the most?

A. Add ezetimibe
B. Add omega-3 fatty acids
C. Add fenofibric acid
D. Switch rosuvastatin to atorvastatin 80 mg daily

2016 ACC Expert Consensus Decision Pathway (ECDP)
Role of Non-statin Therapies

- Endorsed the 2013 ACC/AHA 4 statin benefit group recommendations as initial approach
- Evaluate absolute LDL-C reduction as a “threshold” when considering addition of a non-statin
  - Non-HDL-C as a consideration for patients with diabetes mellitus

2013 ACC/AHA 2013 Blood Cholesterol Guideline:
Statin Intensity

<table>
<thead>
<tr>
<th>High-Intensity</th>
<th>Moderate-Intensity</th>
<th>Low-Intensity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily dose lowers LDL-C on average, by ~30%</td>
<td>Daily dose lowers LDL-C on average, by ~30 to ~50%</td>
<td>Daily dose lowers LDL-C on average, by &lt;30%</td>
</tr>
<tr>
<td>Atorvastatin (40) 80 mg</td>
<td>Rosuvastatin (20) 40 mg</td>
<td>Simvastatin 10 mg</td>
</tr>
<tr>
<td>Atorvastatin (5) 10 mg</td>
<td>Pravastatin 10 mg</td>
<td></td>
</tr>
<tr>
<td>Simvastatin 20–40 mg</td>
<td>Fluvastatin 40 mg</td>
<td>Fluvastatin 10 mg</td>
</tr>
<tr>
<td>Lovastatin 40 mg</td>
<td>Fluvastatin</td>
<td>Pitavastatin 2–4 mg</td>
</tr>
</tbody>
</table>

Specific statins and doses are noted in bold that were evaluated in randomized controlled trials. Statins and doses that are approved by the U.S. FDA but were not tested in the RCTs reviewed are listed in italics.

NLA Recommendations – Part 1

- Primary Target: Non-HDL-C and LDL-C
- Secondary Optional Target: Apo B

NLA=National Lipid Association

 Drugs Affecting Lipoprotein Metabolism

<table>
<thead>
<tr>
<th></th>
<th>LDL-C</th>
<th>HDL-C</th>
<th>TG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statins</td>
<td>↓18-51%</td>
<td>↑5-15%</td>
<td>↓7-30%</td>
</tr>
<tr>
<td>Bile acid sequestrants (BAS)</td>
<td>↑5-10%</td>
<td>↑3-5%</td>
<td>↑10%</td>
</tr>
<tr>
<td>Nicotinic acid</td>
<td>↓1-25%</td>
<td>↑15-35%</td>
<td>↑20-50%</td>
</tr>
<tr>
<td>Fibric Acids</td>
<td>↓5-20%</td>
<td>↑10-20%</td>
<td>↑20-50%</td>
</tr>
<tr>
<td>Ezetimibe</td>
<td>↑1-20%</td>
<td>↑3-5%</td>
<td>↓5-11%</td>
</tr>
<tr>
<td>Omega-3 fatty acids</td>
<td>↓6-12%</td>
<td>↓5-7%</td>
<td>↓19-44%</td>
</tr>
<tr>
<td>PCSK9 inhibitors</td>
<td>↓40-72%</td>
<td>↑10-30%</td>
<td>↓10-17%</td>
</tr>
</tbody>
</table>

For LDL-C lowering

Primarily for hypertriglyceridemia


Clinical ASCVD and Baseline LDL-C ≥ 190 mg/dL on Statin for Secondary Prevention

See enlargement, p. 15
**Ezetimibe – Mechanism of Action**

- Liver Biosynthesis
- Extrahepatic Tissues
- Enterohepatic Circulation
- Intestinal Absorption
- Dietary Cholesterol
- Intestinal Brush Border
- Intestinal Lumen
- Intestinal Lumen
- Intestinal Lumen
- Ezetimibe


**IMPROVE-IT**

- Double-blind randomized trial
- 18,144 patients with acute coronary syndrome
- Age ≥50 years with LDL-C 50–125 mg/dL (50–100 mg/dL if on therapy)
- Simvastatin or ezetimibe/simvastatin for 4.9 years
- Mean LDL-C values:
  - 69.9 mg/dL vs. 53.2 mg/dL


**IMPROVE-IT: Primary Endpoint at Year 7**

- Event Rate (%)
- Time (years since randomization)
- Simvastatin+Lipid-lowering therapy vs. ezetimibe


**PCSK9 Inhibitors: Role in Therapy**

- Alirocumab and Evolocumab FDA approval:
  - Adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (FH) or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C

<table>
<thead>
<tr>
<th>PCSK9 Inhibitor</th>
<th>Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alirocumab</td>
<td>75–150 mg subcutaneously every 2 weeks</td>
</tr>
<tr>
<td>Evolocumab</td>
<td>140 mg subcutaneously every 2 weeks or 420 mg subcutaneously once monthly</td>
</tr>
</tbody>
</table>


**Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors**

- LDL degradation and LDL-R recycling
- PCSK9 mediated LDL-R degradation


See enlargement, p. 16

**Evolocumab (OSLER-1 and OSLER-2)**

- LDL-C (mg/dL)
- Time (weeks)
- Evolocumab + Standard of Care


* All < 0.001
Which of the following is true regarding the addition of a PCSK9 inhibitor in this patient?
A. His insurance company should readily agree to approve a prior authorization because he has a history of ASCVD
B. There are no data demonstrating reduced CV events when added to statin therapy
C. It would be expected to significantly lower his LDL-C, triglycerides, and HDL-C
D. The LDL-C level is expected to be lowered by an additional 50 to 60%

Outcomes Studies with PCSK9 Inhibitors
- Several pending large-scale outcome trials
  - Preliminary Findings
    - Meta-analysis of 24 clinical trials (n=10,159)
      - Reduced MI: OR 0.49 (0.26-0.93)
      - Reduced all-cause mortality: OR 0.45 (0.23-0.86)
    - No increase in serious adverse events compared with no PCSK9 inhibitor

Global Assessment of Plaque ReGression with a PCSK9 Antibody as Measured by IntraVascular Ultrasound (GLAGOV) Trial
- Phase 3, multicenter, double-blind, randomized, placebo-controlled trial
- Evaluated coronary atheroma volume in CAD patients (n=968) receiving optimized statin therapy
  - Randomized to evolocumab 420 mg or placebo subcutaneously monthly
- Primary Endpoint:
  - Percent atheroma volume from baseline to week 78 was significantly lower with evolocumab compared with placebo

On the Horizon
- FOURIER
  - ~27,500 ASCVD patients with LDL-C ≥ 70 mg/dL or non-HDL-C ≥ 100 mg/dL on optimized statin therapy
  - Evolocumab or placebo for up to 5 yr
  - Primary outcome: CV events

Clinical ASCVD and Baseline LDL-C ≥ 190 mg/dL on Statin for Secondary Prevention
- On high-intensity statin
  - Achieved threshold?
  - Expected % LDL-C reduction of 50% is met, but LDL-C value of <70 mg/dL is not met
  - Two non-statin therapies, PCSK9 inhibitor or ezetimibe, can be used
  - Both agents have evidence with statin therapy demonstrating further reduction in CV event risk
  - PCSK9 inhibitor is indicated for this patient
  - Patient most likely to achieve an LDL-C < 70 mg/dL with a PCSK9 inhibitor plus statin therapy
  - Patient may eventually need PCSK9 inhibitor and ezetimibe

See enlargement, p. 16
Case 2

- 52-year old man presents for follow-up in the clinic
- PMH: diabetes, hypertension
- Meds: atorvastatin 40 mg/day, metformin, verapamil
- States adherence to medications + lifestyle modifications (heart healthy diet, recently joined a tennis league)
- LDL-C: Baseline 174 mg/dL, currently 108 mg/dL (↓ 38%)
- Non-HDL-C: Currently 153 mg/dL
- 10-yr ASCVD risk > 7.5%
- Complains of muscle soreness in his back, neck, and lower extremities. Occurs 2-3 x per week. Limits his ability to exercise, but not activities of daily living.

According to the 2013 ACC/AHA Cholesterol Guideline, which of the following do you recommend?

A. Discontinue atorvastatin. Provide documentation in the chart that the patient is intolerant to statin therapy.
B. Switch atorvastatin to fluvastatin XL 80 mg/day. Provide documentation in the chart that the patient is intolerant to atorvastatin.
C. Switch atorvastatin to simvastatin 80 mg/day. Provide documentation in the chart that the patient is intolerant to atorvastatin.
D. Discontinue atorvastatin. Allow muscle symptoms to resolve. Restart atorvastatin 40 mg/day.

NLA Statin Muscle Safety Task Force

Proposed Statin Myalgia Clinical Index Score

<table>
<thead>
<tr>
<th>Clinical Symptoms</th>
<th>Probable 9-11</th>
<th>Unlikely &lt;7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regional distribution/pattern</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Symmetric hip flexors/thigh aches</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>- Symmetric calf aches</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>- Symmetric upper proximal aches</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>- Non-specific asymmetric, intermittent</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Temporal pattern</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Symptom onset &lt;4 weeks</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>- Symptom onset 4-12 weeks</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>- Symptom onset &gt;12 weeks</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>De-challenge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Improves upon withdrawal (&lt;2 weeks)</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>- Improves upon withdrawal (2-4 weeks)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Challenge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Same symptoms recur upon rechallenge &lt;4 weeks</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>- Same symptoms recur upon rechallenge &gt;4 weeks</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>


NLA Statin Intolerance Expert Panel

Statin intolerance

- Clinical syndrome
  - Characterized by inability to tolerate 2 statins (1 at lowest starting dose AND another at any daily dose)
  - Presence of objectionable symptoms (real or perceived) or abnormal lab values
  - Temporally related to statin treatment
  - Reversible upon statin discontinuation
  - Reproducible by rechallenge with other known determinants being excluded (such as hypothyroidism, interacting drugs, concurrent illnesses, significant changes in physical activity or exercise, underlying muscle disease)

**NLA Statin Intolerance Expert Panel Recommendations to Clinicians**

- Clinicians should differentiate statin intolerance from “drug allergy”
  - Drug allergy implies substantial risk with rechallenge
  - Statin intolerance usually does not involve substantial risk for mortality or permanent disability
- In most cases, clinicians and patients should attempt to keep some statin treatment
  - May continue with doses or alternate statin to achieve less LDL-C reduction (e.g., atorvastatin or rosuvastatin 5–10 mg taken once or twice a week may reduce LDL-C by 16–26%)


**2013 ACC/AHA Cholesterol Guideline**

Reasonable to evaluate and treat muscle symptoms (pain, tenderness, stiffness, cramping, weakness, fatigue) using algorithm:

1. Before initiating statin therapy, ask about past or current muscle symptoms
2. With unexplained muscle symptoms or fatigue, evaluate for rhabdomyolysis
3. With mild-moderate muscle symptoms that develop during statin therapy
4. Evaluate for other conditions that may cause muscle symptoms
    - Hypothyroidism, reduced renal or hepatic function, rheumatologic disorders, steroid myopathy, vitamin D deficiency, or primary muscle diseases


**ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies**

- Concurs with 2013 ACC/AHA Cholesterol Guideline methodology to evaluate muscle symptoms
- In addition, recommends rechallenging with > 2 - 3 statins
  - Preferably ones that use different metabolic pathways and have different lipophilicity, and 1 prescribed at the lowest approved dose
- If patient cannot tolerate multiple statins at lowest dose, try alternative dosing strategies (e.g., long-acting statin 3 x week)
- “Non-statin therapies are not considered to be an alternative to evidence-based statin therapy unless statin intolerance has been systematically and rigorously evaluated and documented.”


**Treatment Strategies in Patients with Statin Intolerance**

**The Cleveland Clinic experience**

- Retrospective analysis of 1,605 patients referred for statin intolerance
  - 72.5% were able to tolerate a statin
  - Intermittent statin dosing (n=149) had lower LDL-C reduction compared with daily dosing (n=1014):
    - 21.3% vs 27.7% (P<0.04)
  - Trend toward a decrease in all-cause mortality at 8 years for patients on daily/intermittent statin dosing compared with those who discontinued statin (P=0.08)

Statin Intolerance

- 2013 ACC LDL Think Tank participants identified **perceived** statin intolerance as
  - One of the major barriers to statin adherence
  - A major cause of underutilization of statin therapy

- ACC developed the Statin Intolerance App to
  - Guide clinicians through the management of these patients
  - Helps keep appropriate patients on statin therapy to reduce CV risk

ACC Statin Intolerance App:

**Overall Structure**

The App contains three sections that can be used separately or in series, depending on the knowledge and needs of the clinician.

- Evaluate
- Follow-Up
- Drug Compare

Copyright © 2017, American Society of Health-System Pharmacists, Inc. All rights reserved.
Case 2

- 52-year old man presents for follow-up in the clinic
- PMH: diabetes, HTN
- Meds: atorvastatin 40 mg/day, metformin, lisinopril
- States adherence to medications + lifestyle modifications (heart healthy diet, recently joined a tennis league)
- LDL-C: Baseline 174 mg/dL, currently 108 mg/dL (% 38%)
- Non-HDL-C: Currently 153 mg/dL
- 10-yr ASCVD risk > 7.5%
- Muscle symptoms resolved

According to the ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies, which of the following do you recommend?

A. Pt had less-than-anticipated response on moderate-intensity statin. Start ezetimibe.
B. Pt had anticipated response to high-intensity statin. Start colesevelam to lower LDL-C & A1c
C. Patient had less-than-anticipated response on high-intensity statin. Try alternate high-intensity statin therapy.
D. Clinician and pt should consider potential net ASCVD risk-reduction benefit of adding non-statin & pt preferences.

According to the ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies, at which of the following thresholds may a non-statin be considered after maximizing the statin dose in this patient?

A. LDL-C < 70 mg/dL
B. LDL-C < 100 mg/dL
C. Non-HDL-C < 100 mg/dL
D. LDL-C reduction of at least 30% from baseline
Ages 40-75 (no Clinical ASCVD) + Diabetes

- Same initial clinical steps
- On moderate- or high-intensity statin
- Increase to high-intensity statin if needed
- Achieved threshold?
  - Expected % LDL-C reduction
  - Moderate-intensity: 30-<50%, high-intensity ≥50%
  - May consider LDL-C <100 mg/dL or non-HDL-C <130 mg/dL
  - If not, consider adding ezetimibe (may consider BAS if ezetimibe intolerant + TG <300 mg/dL)
- PCSK9 inhibitor is not indicated

Key Takeaways

- Evidence demonstrates that adding either ezetimibe or adding evolocumab to statin therapy in patients with ASCVD further reduces risk of CV events
- Patients with baseline LDL-C values ≥190 mg/dL and/or ASCVD may need the addition of a non-statin if certain LDL-C thresholds are not achieved
- Multiple strategies are available for the management of patients who report statin-related muscle symptoms to facilitate statin therapy
ACC/AHA 2013 Blood Cholesterol Guideline: Four ASCVD Statin Benefit Groups

- Clinical ASCVD
- LDL-C ≥190 mg/dL
- Diabetes Type 1 or 2, Age 40-75 yr
- ≥7.5% estimated 10-yr ASCVD risk and age 40-75 yr

High-intensity statin if age ≤75 yr
Moderate-intensity statin if age >75 yr or not candidate for high-intensity

ASCVD=atherosclerotic cardiovascular disease
ACC/AHA=American College of Cardiology/American Heart Association

Clinical ASCVD and Baseline LDL-C ≥ 190 mg/dL on Statin for Secondary Prevention

RDN=Registered dietitian nutritionist
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors


Clinical ASCVD and Baseline LDL-C ≥ 190 mg/dL on Statin for Secondary Prevention

NLA Statin Muscle Safety Task Force


Ages 40-75 (no Clinical ASCVD) + Diabetes

Self-Assessment Case Studies

Case 1: A 40-year-old man being evaluated for lipid management

- PMH: heterozygous familial hypercholesterolemia (HeFH), MI 2 years ago, hypertension
- Meds: rosuvastatin 40 mg po daily, carvedilol 12.5 mg po twice daily, ramipril 10 mg po daily, aspirin 81 mg po daily
- States adherence to medications + lifestyle modifications (heart healthy diet, exercises four times weekly)
- LDL-C: Baseline 360 mg/dL, currently 170 mg/dL (↓ >50%)
- Was a 1-pack per day cigarette smoker prior to his MI, but no longer smokes

1. Which of the following changes to this patient’s regimen will reduce his LDL-C value the most?
   a. Add ezetimibe
   b. Add omega-3 fatty acids
   c. Add fenofibric acid
   d. Switch rosuvastatin to atorvastatin 80 mg daily

2. Which of the following is true regarding the addition of a PCSK9 inhibitor in this patient?
   a. His insurance company should readily agree to approve a prior authorization because he has a history of ASCVD
   b. There are no data demonstrating reduced CV events when added to statin therapy
   c. It would be expected to significantly lower his LDL-C, triglycerides, and HDL-C
   d. The LDL-C level is expected to be lowered by an additional 50 to 60%

Case 2, part 1: A 52-year old man presents for follow-up in the clinic

- PMH: diabetes, hypertension
- Meds: atorvastatin 40 mg/day, metformin, verapamil
- States adherence to medications + lifestyle modifications (heart healthy diet, recently joined a tennis league)
- LDL-C: Baseline 174 mg/dL, currently 108 mg/dL (↓ 38%)
- Non-HDL-C: Currently 153 mg/dL
- 10-yr ASCVD risk > 7.5%
- Complains of muscle soreness in his back, neck, and lower extremities. Occurs 2-3 x per week. Limits his ability to exercise, but not activities of daily living.
Ask the Experts: Clinical Case Studies Focusing on Non-statin Therapies for Treating Patients with Hypercholesterolemia

3. According to the 2013 ACC/AHA Cholesterol Guideline, which of the following do you recommend?
   a. Discontinue atorvastatin. Provide documentation in the chart that the patient is intolerant to statin therapy.
   b. Switch atorvastatin to fluvastatin XL 80 mg/day. Provide documentation in the chart that the patient is intolerant to atorvastatin.
   c. Switch atorvastatin to simvastatin 80 mg/day. Provide documentation in the chart that the patient is intolerant to atorvastatin.
   d. Discontinue atorvastatin. Allow muscle symptoms to resolve. Restart atorvastatin 40 mg/day.

Case 2, part 2: 52-year old man presents for follow-up in the clinic
   – PMH: diabetes, HTN
   – Meds: atorvastatin 40 mg/day, metformin, lisinopril
   – States adherence to medications + lifestyle modifications (heart healthy diet, recently joined a tennis league)
   – LDL-C: Baseline 174 mg/dL, currently 108 mg/dL (↓ 38%)
   – Non-HDL-C: Currently 153 mg/dL
   – 10-yr ASCVD risk > 7.5%
   – Muscle symptoms resolved

4. According to the ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies, which of the following do you recommend?
   a. Pt had less-than-anticipated response on moderate-intensity statin. Start ezetimibe.
   b. Pt had anticipated response to high-intensity statin. Start colesevelam to lower LDL-C & A1c
   c. Patient had less-than-anticipated response on high-intensity statin. Try alternate high-intensity statin therapy.
   d. Clinician and pt should consider potential net ASCVD risk-reduction benefit of adding non-statin & pt preferences.

5. According to the ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies, at which of the following thresholds may a non-statin be considered after maximizing the statin dose in this patient?
   a. LDL-C < 70 mg/dL
   b. LDL-C < 100 mg/dL
   c. Non-HDL-C < 100 mg/dL
   d. LDL-C reduction of at least 30% from baseline